EUCTR2010-022433-29-DK进行中（未招募）1 期
Pharmacological intervention on diabetic retinopathy with PGF - LATANO-2
Aarhus University Hospital, Department of Ophthalmology0 个研究点目标入组 50 人开始时间: 2010年8月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Type 1 diabetes mellitus
- •Diabetic retinopathy not requiring photocoagulation treatment
- •Age between 20 and 36 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Present or previous treatment for glaucoma
- •Retinal disease except for diabetic retinopathy
- •Known cardio-vascular disease
研究者
相似试验
已完成
不适用
Pharmacological Intervention in Diabetic RetinopathyDiabetic RetinopathyNCT00619034University of Aarhus87
尚未招募
不适用
Changes in Retinal Blood Vessels seen in Diabetic Retinopathy and following its treatmentCTRI/2020/10/028396Sankara Eye Hospital Bangalore
已完成
不适用
Improving the management of diabetes and its eye problems in IndiaDiabetes and diabetic retinopathyNutritional, Metabolic, EndocrineDiabetes mellitusISRCTN16720335Kurseong Sub-Divisional Hospital110
尚未招募
2 期
Treatment of Diabetic macular edema with intravitreal injection of antiangiogenic agents with or without DexamethasoneMacular EdemaC19.246.099DiabetesRBR-7468j4qniversidade Federal de Pernambuco
进行中（未招募）
1 期
RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Lucentis (Ranibizumab) in patients with visual impairment due to diabetic macular oedema.EUCTR2010-022616-39-GBovartis Pharmaceuticals UK Ltd